Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
This study has been terminated.
( low accrual )
Study NCT00368329 Information provided by Stanford University
First Received on August 22, 2006. Last Updated on July 13, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Esophageal Neoplasms
Carcinoma, Squamous Cell
Adenocarcinoma
Esophageal Cancer
Additional conditions recognized in this trial
Adenocarcinoma, Mucinous
Carcinoma
Esophageal Diseases
Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Interventions listed in this trial
Capecitabine (Xeloda)
[18-F] Fluorodeoxyglucose (FDG)
5-Fluorouracil (5-FU)
Carboplatin
Additional drug interventions recognized in this trial
Capecitabine
Deoxyglucose
Fluorouracil
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Stanford University
Back to top of Main Content
